Vor Biopharma Inc.
VORHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeVor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. With a market capitalization of $980.2M, it sits in small-cap territory. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.
Market Cap
$980.2M
Beta
1.70
P/E (TTM)
—
P/E (Fwd)
-4.83
EPS (TTM)
$-70.40
EPS (Fwd)
$-3.74
ROE
—
ROA
-69.8%
Cash
$491.5M
Total Debt
$2.9M
Free CF
-$188.8M
52W Change
-59.1%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $491.5M in cash comfortably exceeding the $2.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$188.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet.
A beta of 1.70 means VOR is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VOR.